

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Original) A compound selected from the group consisting of N-[4-(2-Hydroxycarbamoylvinyl)benzyl]-4-pyrrolidin-1-ylbenzamide, and 4-Dimethylamino-N-[4-(2-hydroxycarbamoylvinyl)benzyl]benzamide; or a pharmaceutically acceptable salt thereof.
2. (Original) A pharmaceutical composition comprising a compound according to claim 1 in combination with a pharmaceutically acceptable excipient or diluent.
3. (Currently Amended) A method of treating cancer comprising administering the use of a compound according to claim 1 to a patient for the preparation of a medicament having histone deacetylase (HDAC) inhibitory activity.
4. (New) The method of claim 3, wherein the cancer is breast cancer, lung cancer, or stomach cancer.
5. (New) A method of inhibiting histone deacetylase (HDAC) activity in at least one cell comprising providing the compound according to claim 1 to said at least one cell.
6. (New) The method of claim 5, wherein the cell is a breast cancer, lung cancer, or stomach cancer cell.